Dr. Novak is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3401 Enterprise Pkwy
Suite 300
Beachwood, OH 44122Phone+1 216-831-5700Fax+1 216-839-4905
Education & Training
- Johns Hopkins UniversityResidency, Ophthalmology, 1978 - 1982
- Case Western Reserve University/University Hospitals Cleveland Medical CenterInternship, Internal Medicine, 1977 - 1978
- Case Western Reserve University School of MedicineClass of 1977
- Case Western Reserve UniversityBA, 1969 - 1973
Certifications & Licensure
- OH State Medical License 1983 - 2026
- PA State Medical License 1983 - 1984
- MD State Medical License 1980 - 1983
- American Board of Ophthalmology Ophthalmology
Awards, Honors, & Recognition
- Best Doctors in America 2011
- Best Doctors in Cleveland Cleveland Magazine, 2011
- Honor Award American Academy of Ophthalmology, 1992
- Join now to see all
Clinical Trials
- Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy (N) Start of enrollment: 2010 Jun 01
Publications & Presentations
PubMed
- 9 citationsSwitching to brolucizumab: injection intervals and visual, anatomical and safety outcomes at 12 and 18 months in real-world eyes with neovascular age-related macular d...Joseph M Coney, Ryan Zubricky, Samriddhi Buxy Sinha, Nina Sonbolian, Lujia Zhou
International Journal of Retina and Vitreous. 2023-02-01 - One-Year and 18-Month Outcomes in nAMD Patient Eyes Switched to Brolucizumab Alone versus to Brolucizumab Alternating with Other Anti-VEGF Agents.Joseph M Coney, Jasmyne E McCoy, Samriddhi Buxy Sinha, Nina Sonbolian, Lujia Zhou
Clinical Ophthalmology. 2023-01-01
Journal Articles
- VEGFA and VEGFR2 gene polymorphisms and response to anti-vascular endothelial growth factor therapy: comparison of age-related macular degeneration treatments trials (...Hagstrom SA, Ying GS, Pauer GJ, Sturgill-Short GM, Huang J, Maguire MG, Martin DF; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group, JAMA Ophthalmol, 1/1/2014
- Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trialAge-Related Eye Disease Study 2 Research Group, JAMA, 5/15/2013
- Incidence of choroidal neovascularization in the fellow eye in the comparison of age-related macular degeneration treatments trialsMaguire MG, Daniel E, Shah AR, Grunwald JE, et al; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT Research Group), Ophthalmology, 1/1/2013
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- Impact of Lucentis on psychological morbidity in patients with macular edema and neovascularization secondary to retinal vein occlusion.Singerman LJ, Himmelman DR, Singerman B, Thomas A, Newman L, Coney JM, Schartman JP, Novak MA, Program#/Poster# 5466/A662. Association for Research in Vision and Ophthalmology Annual Meeting, Fort Lauderdale, FL, 5/1/2012
Lectures
- Results of the Age-Related Eye Disease Study 2 (AREDS2).Warren, OH - 9/10/2013
- Retinal update on anti-VEGF therapy (with Drs. Coney, Miller, Rao, Schartman, and Zegarra).Vermilion, OH - 12/20/2012
- Lifestyle modifications to prevent the development & progression of macular degeneration.Case Western Reserve University School of Medicine, Cleveland, OH - 11/8/2012
- Join now to see all
Professional Memberships
- Fellow
- Member
- Retina SocietyMember
- Macula SocietyMember
External Links
- Websitehttp://www.retina-doctors.com
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: